A new parenteral cephalosporin. SK&F 59962: in vitro and in vivo antibacterial activity and serum levels in experimental animals.
SK&F 59962, a new parenteral cephalosporin was found to have a high order of in vitro and in vivo antibacterial activity against a broad-spectrum of clinical isolates. When tested in vitro against gram-negative organisms, SK&F 59962 was consistently more active than cefazolin and far superior to cephalothin. This new antibiotic had activity equal to that of cephalothin against gram-positive bacteria. Enterobacter species were found to be susceptible to SK&F 59962. In mouse infection studies using bacterial pathogens, SK&F 59962 had protective activity of the order of that of cefazolin and superior to that of cephalothin. Following parenteral administration the serum profile of SK&F 59962 in the mouse, dog and squirrel monkey was similar to that of cephalothin. SK&F 59962 and cephalothin had lower peak serum concentrations and shorter biologic half-lives than those of cefazolin.
D000818:Animals; D002437:Cefazolin / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D002512:Cephalothin / Q000097:blood / Q000494:pharmacology; D004285:Dogs; D004755:Enterobacteriaceae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D000882:Haplorhini; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007711:Klebsiella pneumoniae / Q000187:drug effects; D051379:Mice; D012482:Salmonella paratyphi A / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D002511:Cephalosporins; D002437:Cefazolin; D002512:Cephalothin